SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 1, 2002
Indevus Pharmaceuticals, Inc.
-----------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-18728 04-3047911
--------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
One Ledgemont Center
99 Hayden Avenue
Lexington, Ma 02421-7966
----------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code:
(781-861-8444)
Interneuron Pharmaceuticals, Inc.
---------------------------------
(Former Name)
ITEM 5. Other Events and Regulation FD Disclosure.
------- ------------------------------------------
On July 1, 2002, Indevus Pharmaceuticals, Inc., formerly known as
Interneuron Pharmaceuticals, Inc. (the "Company"), issued a press release
containing the information attached hereto as Exhibit 99.1 announcing the
Company licensed exclusive worldwide rights from Atlantic Technology Ventures,
Inc. (OTC BB:ATLC.OB) to CT-3, a novel anti-inflammatory and analgesic compound
currently in clinical development. A director of the Company is a shareholder of
Atlantic Technology Ventures, and the transaction was approved by all of the
disinterested directors of the Company. As a part of the press release, the
Company also updated the status of the other compounds which are currently in
the Company's product pipeline including, the execution of a non-binding
Memorandum of Agreement with a privately held biotechnology company to fund the
further development of citicoline. The execution of a binding agreement is
contingent upon a number of conditions and there can be no assurance that a
binding agreement will be entered into on the terms set forth in the Memorandum
of Agreement or at all. The press release is incorporated herein by reference.
The exhibit hereto contains forward-looking statements that involve risks
and uncertainties that could cause our actual results and financial condition to
differ materially from those anticipated by the forward-looking statements. The
words "believe", "expect", "anticipate", "intend", "plan", "estimate" or other
expressions which are predictions of or indicate future events and trends do not
relate to historical matters but identify forward-looking statements. Risks and
uncertainties related to forward-looking statements are set forth in the
Company's filings under the Securities Act of 1933 and the Securities Exchange
Act of 1934 under "Risk Factors" and elsewhere in, or incorporated by reference
into, the Company's Form 10-K for its fiscal year ended September 30, 2001 and
elsewhere.
Item 7. Financial Statements and Exhibits.
------- ----------------------------------
(a) Financial Statements of Business Acquired: N/A
(b) Pro Forma Financial Information: N/A
-2-
(c) Exhibits:
Exhibit No. Description of Exhibit
----------- ----------------------
Exhibit 99.1 Press Release dated July 1, 2002
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERNEURON PHARMACEUTICALS, INC.
Dated: July 3, 2002 By:
/s/ Glenn L. Cooper, M.D.
-------------------------
Glenn L. Cooper, M.D.
President, Chief Executive Officer and Chairman
-3-